HK1038886A1 - Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors for the preparation of a pharmaceutical composition for treatment of kidney disorder. - Google Patents

Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors for the preparation of a pharmaceutical composition for treatment of kidney disorder.

Info

Publication number
HK1038886A1
HK1038886A1 HK02100508A HK02100508A HK1038886A1 HK 1038886 A1 HK1038886 A1 HK 1038886A1 HK 02100508 A HK02100508 A HK 02100508A HK 02100508 A HK02100508 A HK 02100508A HK 1038886 A1 HK1038886 A1 HK 1038886A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
beta1
tgf
preparation
treatment
Prior art date
Application number
HK02100508A
Other versions
HK1038886B (en
Inventor
Dominic Cosgrove
Original Assignee
Boys Town Nat Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/011073 external-priority patent/WO1999061040A2/en
Application filed by Boys Town Nat Res Hospital filed Critical Boys Town Nat Res Hospital
Publication of HK1038886A1 publication Critical patent/HK1038886A1/en
Publication of HK1038886B publication Critical patent/HK1038886B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
HK02100508.3A 1998-05-22 2002-01-22 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KIDNEY DISORDER HK1038886B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
HK1038886A1 true HK1038886A1 (en) 2002-04-04
HK1038886B HK1038886B (en) 2005-09-23

Family

ID=27375439

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100508.3A HK1038886B (en) 1998-05-22 2002-01-22 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF KIDNEY DISORDER

Country Status (2)

Country Link
KR (1) KR100574597B1 (en)
HK (1) HK1038886B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116639C2 (en) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Methods for treatment of alport syndrome

Also Published As

Publication number Publication date
KR20010052390A (en) 2001-06-25
KR100574597B1 (en) 2006-04-28
HK1038886B (en) 2005-09-23

Similar Documents

Publication Publication Date Title
HK1076723A1 (en) Highly selective norepinephrine reuptake inhibitors and the use for the preparation of the medicament thereof
HK1065037A1 (en) Indazole compounds and pharmaceutical compositionsfor inhibiting protein kinases, and methods for t heir use
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
HK1034455A1 (en) Oral pharmaceutical extended release dosage form.
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
NZ513889A (en) Kappa agonist compounds, pharmaceutical formulations and methods of prevention and treatment of pruritus therewith
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
HUP0200588A2 (en) Diaryl derivatives and pharmaceutical compositions containing them and their use
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
IL138416A (en) Use of dexmedetomidine or pharmaceutical acceptable salt thereof for preparation of a sedative
HUP0104175A3 (en) Pharmaceutical composition comprising a combination of dextro- and laevo- isomers of sotalol
ZA971132B (en) New cephem compounds and pharmaceutical use thereof.
HUP0203212A3 (en) Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions
HU9802716D0 (en) Pharmaceutical composition of analgesic activity
HUP0103712A3 (en) Salts of paroxetine, process for their preparation and their pharmaceutical use
AU4307800A (en) New indication for use of antiepileptic agents and medicines
HUP0201629A3 (en) Pharmaceutical complex containing eletriptan and cyclodextrin-derivative, pharmaceutical composition containing it, process for its preparation and its use
HK1038886A1 (en) Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors for the preparation of a pharmaceutical composition for treatment of kidney disorder.
IL141031A0 (en) New pharmaceutical uses for nos inhibitors
HUP0202377A2 (en) N-substituted perhydrodiazines, preparation and use thereof
IL139687A0 (en) USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE
IL123341A0 (en) Pharmaceutical dosage form
HU9702296D0 (en) Analgesic pharmaceutical composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090519